Search Results

You are looking at 1 - 10 of 33 items for :

  • Cabergoline x
Clear All
Open access

Emilia Sbardella, George Farah, Ahmed Fathelrahman, Simon Cudlip, Olaf Ansorge, Niki Karavitaki and Ashley B Grossman

neuro-ophthalmological emergencies. We present a patient with a macroprolactinoma who showed an unexpected and severe escape from cabergoline treatment. The tumour was originally a typical adenoma sensitive to DAs therapy, but later it became resistant

Open access

Lisa Burback

prolactin in a patient with no previous psychiatric history who developed severe psychiatric side effects from cabergoline. Aripiprazole may be a novel and well tolerated therapy for the treatment of hyperprolactinemia due to microprolactinomas. Further

Open access

Wael M Almistehi and Mussa H Almalki

bromocriptine and cabergoline (CAB) until conception is safe; however, there is scant evidence to support the idea that continuing the use of bromocriptine or CAB is safe during pregnancy. The Endocrine Society guidelines recommend discontinuing DAs as soon as

Open access

L I Astaf’eva, Y G Sidneva, B A Kadashev, P L Kalinin, G A Melnichenko and S A Agadzhanian

fertility ( 3 , 4 , 5 , 6 ). We present a woman with a giant prolactinoma. Despite the giant size of the tumour which invaded the skull base bones, high PRL level and primary amenorrhoea, cabergoline was effective in normalization of the PRL level, tumour

Open access

J K Prague, C L Ward, O G Mustafa, B C Whitelaw, A King, N W Thomas and J Gilbert

). Treatment Cabergoline was commenced (initially 250 μg twice/week) causing a dramatic reduction in tumour size and resolution of his neurological symptoms. The prolactin level continued to fall with subsequent normalisation of his testosterone level

Open access

Maryam Rahman, Ignacio Jusué-Torres, Abdulrahman Alkabbani, Roberto Salvatori, Fausto J Rodríguez and Alfredo Quinones-Hinojosa

. Imaging results from the time of diagnosis are not available, but she was diagnosed with a microadenoma. She was successfully treated with cabergoline with normalization of serum prolactin and regularization of menstrual periods. She was stable on this

Open access

Benedetta Zampetti, Giorgia Simonetti, Roberto Attanasio, Antonio Silvani and Renato Cozzi

medication with dopamine-agonist drugs, mainly cabergoline (Cab), capable of normalizing PRL levels and restore eugonadism in most cases, as well as to shrink tumor, thus relieving local compression ( 1 , 2 ). Approximately 11% of prolactinomas are resistant

Open access

Niki Margari and Simon Page

(blue arrow, plate A). Following treatment with cabergoline, the soft tissue mass reduced in size significantly after 3 months of therapy (blue arrow, plate B). During the admission, the endocrinology team were also involved. Inpatient

Open access

Ellena Cotton and David Ray

pituitary prolactinoma. The tumour was responsive to cabergoline therapy. Case presentation A 50-year-old woman presented, in 2010, with galactorrhoea and oligomenorrhea of 4 years. Her past medical history included a right nephrectomy following a

Open access

Michelle Maher, Federico Roncaroli, Nigel Mendoza, Karim Meeran, Natalie Canham, Monika Kosicka-Slawinska, Birgitta Bernhard, David Collier, Juliana Drummond, Kassiani Skordilis, Nicola Tufton, Anastasia Gontsarova, Niamh Martin, Márta Korbonits and Florian Wernig

Goldmann visual field perimetry, whilst cranial nerve examination was normal ( Fig. 1A ). Figure 1 Visual field of the patient at diagnosis (A), on cabergoline treatment (B), before surgery (C) and after surgery (D). Investigation MRI